Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects
Characteristics of Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects
1 other identifier
observational
60
1 country
1
Brief Summary
Glucose fluctuations present not only in patients with diabetes mellitus but also in subjects with normal glucose tolerance or impaired glucose regulation. People with Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome are at risk of impaired glucose metabolism. Glycemic variability is poorly studied in the nondiabetic individuals. The aim of the study is to investigate the characteristics of glucose fluctuations in the newly diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome individuals.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Dec 2014
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2014
CompletedFirst Submitted
Initial submission to the registry
October 9, 2015
CompletedFirst Posted
Study publicly available on registry
October 14, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
January 7, 2018
CompletedJanuary 23, 2018
December 1, 2014
3.1 years
October 9, 2015
January 20, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Continuous glucose profiles of mean data of 24-hour continuous glucose monitoring by the CGMS Gold
The monitoring results consisted of one curve and 5 parameters
3 days
Secondary Outcomes (4)
The mean amplitude of glycemic excursion of newly diagnosed GH adenoma patients
3 days
The mean amplitude of glycemic excursion of newly diagnosed Cushing Syndrome patients during the 3 days monitored by CGMS Gold
3 days
The correlation of MAGE and IGF-1 in newly diagnosed GH adenoma patients
6 months
The correlation of MAGE and cortison in newly diagnosed Cushing Syndrome patients
6 months
Interventions
Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome in our department will be monitored blood glucose by CGMS Gold.
Eligibility Criteria
Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome
You may qualify if:
- newly diagnosed GH-releasing pituitary adenoma
- newly diagnosed Cushing Syndrome
You may not qualify if:
- history of diabetes mellitus and being treated with drugs
- being treated with drugs which affect glucose metabolism in the lately 3 months
- with other hormones affecting glucose metabolism secreted abnormally by pituitary
- serious comorbidity like malignant tumour, severe hepatosis or nephropathy, serious hypertension(blood pressure\> 180/110mmhg)
- pregnant or breastfeeding women
- patients allergic to patches or metal
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Huashan Hospitallead
Study Sites (1)
Xiaolong Zhao
Jing’an, Shanghai Municipality, 20041, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
yiming li
director of the endocrinology department
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator, Clinical Associate Professor of Endocrinology department
Study Record Dates
First Submitted
October 9, 2015
First Posted
October 14, 2015
Study Start
December 1, 2014
Primary Completion
December 31, 2017
Study Completion
January 7, 2018
Last Updated
January 23, 2018
Record last verified: 2014-12